GLP1R and metabolic dysfunction-associated steatohepatitis: A promising class of therapeutics for the treatment of MASH are GLP-1 receptor agonists (GLP-1RAs)47, which have also transformed the treatment landscape for people living with T2D and obesity based on their ability to regulate glucose and cause weight loss through reduced caloric intake, respectively22,48.